医药行业重磅消息！2025医保及商保目录公布，多款新药入选

Core Insights - The National Healthcare Security Administration and other departments have issued the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog" and the "Commercial Health Insurance Innovative Drug Catalog," which will take effect on January 1, 2026 [1] - The latest adjustment to the medical insurance drug catalog includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [1] - The first version of the commercial health insurance innovative drug catalog includes 19 drugs, featuring CAR-T therapies for cancer treatment and drugs for Alzheimer's disease [1] Company and Industry Summary - Fosun Pharma's Luwo Mei Tini tablets will be included in the 2025 medical insurance catalog, while Beihai Kangcheng's injectable Vilazodone will enter the commercial health insurance innovative drug catalog [1] - Five CAR-T drugs have been included in the commercial health insurance innovative drug catalog, which are Fosun Kairui's Aki Lunsai injection, WuXi AppTec's Rui Ji Aolunsai injection, HeYuan Biotech's Na Ji Aolunsai injection, Reindeer Biotech's Yi Ji Aolunsai injection, and Keji Pharma's Ze Wo Ji Aolunsai injection [1] - Innovative drugs included in both medical insurance and commercial health insurance are mostly in the early stages of market penetration, and the release of policy benefits is expected to accelerate their market growth [1] - The gradual promotion of commercial health insurance is anticipated to increase the payment sources for innovative drugs, fostering a positive cycle in the payment sector [1] - The Hang Seng Medical ETF (159892) focuses on the innovative drug industry and is expected to benefit from the updates to the medical insurance catalog and potential interest rate cuts by the Federal Reserve [1]